Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04007926
Other study ID # 265320
Secondary ID
Status Suspended
Phase N/A
First received
Last updated
Start date August 2021
Est. completion date January 2025

Study information

Verified date October 2020
Source University of Glasgow
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study determines the effect of aerobic and resistance exercise training on whole-body and skeletal muscle insulin sensitivity in south Asians and evaluate the mechanisms which contribute to improvements in insulin sensitivity after exercise training.


Description:

South Asians (SA) have 2-4 fold higher risk of type 2 diabetes and develop the disease at lower body weights and younger ages than white Europeans. Lower cardiorespiratory fitness and capacity for muscle fat oxidation contributes substantially to SAs' greater insulin resistance, the extent to which this can be improved by exercise training is unclear. This randomised controlled trial will investigate the effects of a 12-week aerobic or resistance exercise training intervention on insulin sensitivity (hyperinsulinaemic-euglycaemic clamp) in South Asian adults (22 control, 22 aerobic exercise group and 22 resistance exercise group). The study will also explore the mechanisms within skeletal muscle which mediate these changes by evaluating aerobic and resistance exercise-training induced changes: in basal and insulin-stimulated microvascular blood volume (using contrast-enhanced ultrasound); skeletal muscle mitochondrial function; and lipid droplet morphology and spatial interaction with mitochrondria, muscle fibre capillarisation, endothelial content of key enzymes controlling dilation/constriction and GLUT-4 translocation (using confocal immunofluorescence microscopy and transmission electron microscopy methods). Thus, this work will integrate physiological and molecular data to determine the extent to which exercise training can improve insulin sensitivity in SA and the mechanisms underpinning this improvement. This knowledge is important for optimising diabetes prevention interventions in SAs and identification of potential novel therapeutic targets.


Recruitment information / eligibility

Status Suspended
Enrollment 66
Est. completion date January 2025
Est. primary completion date March 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria:

- Male

- South Asian ethnicity (self-report of both parents of Indian, Pakistani, Bangladeshi or Sri Lankan origin)

- Age 30-65 years

- At least 10% 10-year risk of developing type 2 diabetes, determined using the QDiabetesĀ®2018 risk score (http://qdiabetes.org/2018/index.php)

Exclusion Criteria:

- Female

- Diabetes (physician diagnosed or HbA1c =48 mmol/mol on screening)

- History of cardiovascular disease

- Hypertension (taking anti-hypertensives or BP consistently = 150/90 mmHg on screening).

- Regular participation in vigorous physical activity

- Regular participation in resistance exercise

- Current smoking

- Taking drugs or supplements thought to affect carbohydrate or lipid metabolism

- Taking drugs affecting blood clotting (e.g. aspirin)

- Current treatment with anti-obesity drugs

- Any other significant illness that would prevent full participation in the study

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Aerobic exercise programme
Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.
Resistance exercise programme
Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.

Locations

Country Name City State
United Kingdom University of Glasgow Glasgow

Sponsors (2)

Lead Sponsor Collaborator
University of Glasgow Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Whole-body Insulin sensitivity Change in whole-body insulin sensitivity measured by hyperinsulinaemic-euglycaemic clamp. Change between baseline and 12 weeks.
Secondary Insulin-stimulated GLUT4 translocation Change in insulin-stimulated GLUT4 translocation in muscle biopsies from vastus lateralis using immunofluorescence microscopy Change between baseline and 12 weeks.
Secondary Microvascular blood volume Change in fold-increase in insulin stimulated quadriceps muscle blood volume measured using contrast enhanced ultrasound. Change between baseline and 12 weeks.
Secondary Muscle mitochondrial function Change in mitochondrial function (oxygen consumption rate) in isolated skeletal muscle mitochondria from the vastus lateralis measured using respirometry Change between baseline and 12 weeks.
Secondary Lipid droplet content in skeletal muscle Change in fibre type-specific (type 1 and type 2) and subcellular-specific (subsarcolemmal and intermyofibrillar) lipid droplet content in muscle biopsies from vastus lateralis using immunofluorescence microscopy Change between baseline and 12 weeks.
Secondary Lipid droplet proximity to mitochondria in skeletal muscle Change in proportion of lipid droplets in contact with mitochondria in subsarcolemmal and intermyofibrillar compartments of type 1 and type 2 muscle fibres in muscle biopsies from vastus lateralis using immunofluorescence microscopy Change between baseline and 12 weeks.
Secondary Microvascular density in skeletal muscle Change in fibre-type specific capillarisation in muscle biopsies from vastus lateralis Change between baseline and 12 weeks.
Secondary Change in enzymes controlling insulin-mediated increases in perfusion in skeletal muscle Change in endothelial specific protein content and phosphorylation of key microvascular enzymes in muscle biopsies from vastus lateralis assessed using quantitative immunofluorescence. Change between baseline and 12 weeks.
Secondary Maximal oxygen uptake Change in maximal oxygen uptake consumption assessed using continuous incremental uphill walking protocol until volitional exhaustion. Change between baseline and 12 weeks.
Secondary Muscle maximal voluntary contraction Change in knee extensor muscles maximal voluntary contraction Change between baseline and 12 weeks.
Secondary Lower body muscle strength Change in 1-RM (one maximal repetition) (kg) for leg press. Change between baseline and 12 weeks.
Secondary Upper body muscle strength Change in 1-RM (one maximal repetition) (kg) for chest press. Change between baseline and 12 weeks.
Secondary Grip strength Change in grip strength (kg). Change between baseline and 12 weeks.
Secondary Fat mass Change in fat mass measured with bioelectrical impedance analysis (BIA). Change between baseline and 12 weeks.
Secondary Fat-free mass Change in fat-free mass measured with bioelectrical impedance analysis (BIA). Change between baseline and 12 weeks.
Secondary Weight Change in weight (kg). Change between baseline and 12 weeks.
Secondary Waist circumference Change in waist circumference (cm) Change between baseline and 12 weeks.
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03383822 - Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04203238 - Potato Research for Enhancing Metabolic Outcomes N/A
Recruiting NCT03658564 - Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance N/A
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03627104 - Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT01809288 - Identifying Risk for Diabetes and Heart Disease in Women
Completed NCT04642482 - Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A
Withdrawn NCT04741204 - Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Phase 4